Could a weekly shot stop post-transplant weight gain?
NCT ID NCT05424003
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether semaglutide (a drug used for diabetes and weight loss) can prevent weight gain and fatty liver disease in people who have recently had a liver transplant. About 50 adults who had a transplant 2 to 6 months ago will receive either semaglutide or a placebo. Researchers will track weight changes and use MRI scans to check for fatty liver buildup.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new MRI technique could see inside the Liver's metabolism without a biopsy
- Could a common b vitamin tame fatty liver?
- Can a sugar test reveal how fatty liver begins in obese adolescents?
- Could a daily dose of citrus fiber tame fatty liver inflammation?
- Fatty liver disease: a new biobank aims to unlock the secrets of a silent epidemic
- Calorie cutting may reverse a key step toward diabetes